The decline in estrogen during menopause affects more than appearance. Many women experience thinner, drier, and more fragile skin, along with slower wound healing and reduced skin resilience. These physiological changes can significantly impact daily comfort and overall quality of life.

In November 2025, the U.S. FDA removed the boxed warning from menopausal hormone therapy products, marking an important shift in clinical guidance. The decision has renewed interest in the broader benefits of hormone therapy, including its potential role in maintaining skin health in addition to supporting menopausal care.

Estrogen plays a vital role in preserving healthy skin because its receptors are found throughout skin tissue. As estrogen levels decline after menopause, collagen production falls by approximately 1–2% each year during the early postmenopausal period. Skin becomes thinner, loses moisture more easily, and its protective barrier weakens.

These biological changes contribute to increased skin fragility, slower wound healing, and accelerated visible aging. Understanding the relationship between estrogen and skin health may help advance personalized approaches to healthy aging and improve quality of life for postmenopausal women.

Source: https://dermatology.smhs.gwu.edu/news/beyond-hot-flashes-what-fdas-hormone-therapy-decision-means-aging-skin